Document is current

Article History

Received: 14 November 2025

Accepted: 9 February 2026

First Online: 21 February 2026

Declarations

:

: This was a non-interventional, qualitative interview study conducted in the United States, United Kingdom, Germany, and Japan. Ethical approval or exemption was obtained in accordance with local regulations in each country . The study was conducted in line with the Declaration of Helsinki and, where applicable, Good Clinical Practice and Institutional Review Board (IRB) requirements.

: Informed consent was obtained from all individual participants included in the study.

: Not applicable, as no identifiable personal data, images, or quotes have been included in the manuscript.

: B. D. Stein has received grants, support for attending and travel to meetings, and honoraria in an advisory role from Roche Canada, unrelated to this manuscript. L. Downes is an employee of Roche. N. Sheahan has received grants on behalf of Global Colon Cancer Association from Amgen, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Exeloxis, GSK, Novartis, Roche and Takeda. Z. Maravic has received grants on behalf of Digestive Cancers Europe from Amgen, Astellas, AstraZeneca, Bayer, BeiGene, BI, BMS, Daiichi-Sankyo, GSK, Jazz Pharmaceuticals, Merck, MSD, Novartis, Pierre-Fabre, Roche, Sandoz, Servier and Takeda. A. Kawazone has received grants from AstraZeneca and Abbvie, honoraria from Abbvie, Taiho Pharmaceutical, Bristol Myers Squibb, Merck Serono, Ono and Daiichi Sankyo, and has participated in data safety monitoring/advisory boards for Zymeworks, Abbvie and GSK. I. Guillemin is an employee of IQVIA who received payment as a consultancy company for Roche. M. Leibfried is an employee of Genentech. P. Trask is an employee of and holds stock options in Roche/Genentech. The results of the study have been presented clearly, honestly, and without fabrication, falsification, or inappropriate data manipulation.